Effect of Leuprolide and Dexamethasone on Hair Growth and Hormone Levels in Hirsute Women: The Relative Importance of the Ovary and the Adrenal in the Pathogenesis of Hirsutism*
- 1 April 1990
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 70 (4), 1096-1102
- https://doi.org/10.1210/jcem-70-4-1096
Abstract
Ten hirsute women with polycystic ovarian syndrome (PCO) and nine with idiopathic hirsutism (IH) underwent selective ovarian suppression with leuprolide for 5-6 months and then were randomized to receive, in addition, dexamethasone or placebo for 4 more months. Serum hormone levels and hair growth rates were determined before and after each treatment period. During the initial treatment period with leuprolide alone, testosterone decreased by 54 .+-. 6% (mean .+-. SEM) in PCO and by 36 .+-. 3% in IH (P = 0.02). Androstenedione decreased by 53 .+-. 6% in PCO and by 31 .+-. 7% in IH (P = 0.02). Androstanediol glucuronide (Adiol-G) decreased by 14 .+-. 6% in PCO and by 7 .+-. 3% in IH. There was no change in dehydroepiandrosterone sulfate (DHEAS). While initial serum androgen levels were higher in PCO than in IH, they were similar after ovarian suppression in the two groups. After ovarian suppression, Adiol-G was more consistently correlated with testosterone and androstenedione than was DHEAS, suggesting that Adiol-G may be a better marker than DHEAS of adrenal androgen secretion. Hair growth rates decreased by 37 .+-. 6% in PCO and by 14 .+-. 10% in IH (P = 0.07). The change in hair growth correlated with the change in androstenedione (r = 0.66; P = 0.002), but not significantly with the change in testosterone (r = 0.29; P = 0.2). After the addition of dexamethasone therapy (0.5 mg daily), testosterone, androstenedione, and DHEAS levels fell to near or below assay detection limits, while Adiol-G decreased by 80 .+-. 3%. Hair growth rates decreased slightly more in women during dexamethasone (46 .+-. 6%) than during placebo (26 .+-. 9%; P = 0.18). In summary, the ovary was the major source of circulating testosterone and androstenedione in PCO. The adrenal contributed a substantial minority of these hormones in PCO and was the major source of androgen secretion in IH. Adrenal hyperandrogenism was common in both IH and PCO. Hair growth rates correlated best with changes in serum androstenedione levels. Adiol-G, which was derived primarily from adrenal precursors, was a better marker of adrenal androgen secretion than was DHEAS in these subjects.This publication has 18 references indexed in Scilit:
- HirsutismAnnals of Internal Medicine, 1987
- Determination of the Source(s) of Androgen Overproduction in Hirsutism Associated with Polycystic Ovary Syndrome by Simultaneous Adrenal and Ovarian Venous Catheterization. Comparison with the Dexamethasone Suppression TestJournal of Clinical Endocrinology & Metabolism, 1986
- Treatment of Hirsutism with a Gonadotropin-Releasing Hormone Agonist (Nafarelin)∗Journal of Clinical Endocrinology & Metabolism, 1986
- Comparative Effects of Cyproterone Acetate or a Long-Acting Gonadotropin-Releasing Hormone Agonist in Polycystic Ovarian DiseaseJournal of Clinical Endocrinology & Metabolism, 1986
- Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism.BMJ, 1986
- Effect of gonadotrophin-releasing hormone analogue (GnRH-A) administration on serum gonadotrophin and steroid levels in patients with polycystic ovarian diseaseActa Endocrinologica, 1986
- Steroid Secretion in Polycystic Ovarian Disease after Ovarian Suppression by a Long-Acting Gonadotropin-Releasing Hormone Agonist*Journal of Clinical Endocrinology & Metabolism, 1983
- Diagnostic Evaluation of Hirsutism in Women by Selective Bilateral Adrenal and Ovarian Venous CatheterizationFertility and Sterility, 1978
- Idiopathic Hirsutism — An Ovarian AbnormalityNew England Journal of Medicine, 1976
- CLINICAL ASSESSMENT OF BODY HAIR GROWTH IN WOMENJournal of Clinical Endocrinology & Metabolism, 1961